Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies
March 22, 2023 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce that it is receiving advisory services and up to...
Rakovina Therapeutics Inc. Announces Plan to Apply to Extend Warrant Expiry Dates
March 10, 2023 20:36 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) announces that it may apply to the TSX Venture Exchange (the “TSXV”) to extend...
Rakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summit
January 26, 2023 23:45 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), is pleased to announce a scientific presentation at the 6th Annual DDR...
Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
November 23, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update
November 17, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma
November 14, 2022 09:00 ET
|
Rakovina Therapeutics Inc
Publication to be available on pre-print server, bioRxiv, and will be submitted for scientific journal peer-review VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rakovina...
Rakovina Therapeutics Announces Preclinical Data Presentation at the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
October 31, 2022 08:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Announces Upcoming Scientific Conference Presentations
September 28, 2022 08:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update
August 11, 2022 15:09 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Announces Results from Annual General Meeting
June 23, 2022 19:07 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...